510(k) device
Acticlot, Model 824
American Diagnostica, Inc. · Test, Time, Prothrombin (GJS, Class II) · First FDA decision Oct 17, 2005, newest Oct 17, 2005Anemia, clotting and blood disordersStroke prevention in atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Acticlot"
MAUDE reports
0
Brand "Acticlot", since 2015
PubMed studies
3
Mentioning "Acticlot"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Acticlot, Model 824
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ACTICLOT, MODEL 824510(k)
K052124 · Decided Oct 17, 2005 · 73 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation ManagementNational determinationOn the books190.11Updated Nov 4, 2026
- Prothrombin Time (PT)National determinationOn the books190.17Updated Oct 1, 2026
- Prothrombin Time (INR) Monitor for Home Anticoagulation ManagementNational analysisReview closedCAG-00087RUpdated Sep 21, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Swelling of Limb)Coding analysisReview closedCAG-00201NUpdated Sep 15, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Pre-operative Examinations)Coding analysisReview closedCAG-00184NUpdated Sep 15, 2026
- Prothrombin Time and Fecal Occult Blood (Revision of ICD-9-CM Codes for Injury to Gastrointestinal Tract)Coding analysisReview closedCAG-00187NUpdated Sep 15, 2026
- Prothrombin Time (PT) NCD 190.17 (Addition of ICD-9-CM diagnosis code 197.7 Secondary Malignant Neoplasm of Liver)Coding analysisReview closedCAG-00404NUpdated Sep 15, 2026
- Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) tests (Removal of Unspecified Joint Replacements)Coding analysisReview closedCAG-00246NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Acticlot", any status and sponsor, newest update first.
No registered device study names "Acticlot".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Acticlot", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code GJS
12,207 reports: 11,507 malfunction, 644 injury, 34 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0779-2007 · Started Feb 28, 2007 · Posted by FDA May 3, 2007
Reason given: Stability of product not assured. An increase of clotting time for both normal and abnormal plasmas
Cause as FDA categorized it: Other · Device type: Reagent, Russel Viper Venom (GIR)
Published research
The most relevant PubMed records for "Acticlot"[tiab]. The summary above synthesizes these.
- An evaluation of screening tests for defects in the protein C pathway: commercial kits lack sensitivity and specificity.
Gardiner C, Cooper PC, Makris M, et al. · Blood Coagul Fibrinolysis · 2002Comparative Study, Evaluation Study
- Prevalence of resistence to activated protein C (APC-resistance) in blood donors in Kosovo.
Mekaj Y, Zhubi B, Hoxha H, et al. · Bosn J Basic Med Sci · 2009Research Support, Non-U.S. Gov't
- Novel Flowable Hemostatic Agent ActiClot: Efficacy and Safety Assessment in Rat and Porcine Models.
Kim HJ, Lee SK, Ko YJ, et al. · J Clin Med · 2024
Other devices of this type
Also filed under product code GJS.
- microINR SystemIline Microsystems, S.L. · 510(k) 2025
- CoaguChek XS Plus SystemRoche Diagnostics · 510(k) 2025
- Coag-Sense Prothrombin (PT) / INR Monitoring System for Patient Self-TestingCoagusense, Inc. · 510(k) 2022
- CoaguChek XS Pro SystemRoche Diagnostics · 510(k) 2018
- Hemosil Recombiplastin 2G (8 Ml Vial)Instrumentation Laboratory CO · 510(k) 2014
- Coaguchek Xs SystemRoche Diagnostics Corp. · 510(k) 2007
- Xprecia Prime Coagulation SystemUniversal Biosensors Pty, Ltd. · 510(k) 2024
- i-STAT PTplus Cartridge with the i-STAT 1 SystemAbbott Laboratories · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.